US 12384761
Imidazolo indazole compounds as JAK inhibitors
granted A61PA61P11/00
Quick answer
US patent 12384761 (Imidazolo indazole compounds as JAK inhibitors) held by Theravance Biopharma R&D IP, LLC expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Theravance Biopharma R&D IP, LLC
- Grant date
- Tue Aug 12 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 21
- CPC classes
- A61P, A61P11/00